ID: ALA3805168

Max Phase: Preclinical

Molecular Formula: C14H11FN2O

Molecular Weight: 242.25

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1NC(c2ccc(F)cc2)Nc2ccccc21

Standard InChI:  InChI=1S/C14H11FN2O/c15-10-7-5-9(6-8-10)13-16-12-4-2-1-3-11(12)14(18)17-13/h1-8,13,16H,(H,17,18)

Standard InChI Key:  TVPPBWCYGUMJAW-UHFFFAOYSA-N

Associated Targets(non-human)

Cathepsin H 102 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 242.25Molecular Weight (Monoisotopic): 242.0855AlogP: 2.68#Rotatable Bonds: 1
Polar Surface Area: 41.13Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 10.77CX Basic pKa: CX LogP: 3.19CX LogD: 3.19
Aromatic Rings: 2Heavy Atoms: 18QED Weighted: 0.81Np Likeness Score: -0.90

References

1. Khan I, Zaib S, Batool S, Abbas N, Ashraf Z, Iqbal J, Saeed A..  (2016)  Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: An update on the development of synthetic methods and pharmacological diversification.,  24  (11): [PMID:27112448] [10.1016/j.bmc.2016.03.031]

Source